戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 eaching applications in drug development and molecular pharmacology.
2 nflicting data from available structures and molecular pharmacology.
3 3 therapies, but little is known about their molecular pharmacology.
4 m conflicting data in crystal structures and molecular pharmacology.
5 ignpost for an era spanning over 40 years in molecular pharmacology.
6  major goal in the field of neuroscience and molecular pharmacology.
7 ted quinoline drugs may have quite different molecular pharmacology.
8 grate large databases on gene expression and molecular pharmacology.
9 he article by Cassel et al. in this issue of Molecular Pharmacology, address this question and demons
10                        976) in this issue of Molecular Pharmacology addresses whether this constituti
11 tribution by Micheva et al. in this issue of Molecular Pharmacology adds to our understanding of the
12 erential binding to a given target, detailed molecular pharmacology analysis accurately predicts util
13                                  Here we use molecular pharmacology and cryo-EM structural elucidatio
14                                 By combining molecular pharmacology and genetic tools in INS-1E cells
15                                              Molecular pharmacology and mutagenesis studies indicate
16 pose that precise determinations of GHSR(1a) molecular pharmacology and pathway-specific physiologica
17 detection will facilitate exploration of the molecular pharmacology and plasticity of exocytosis at m
18 aging will facilitate the exploration of the molecular pharmacology and plasticity of exocytosis at M
19 techniques to foster understanding of A(1)AR molecular pharmacology and signaling in living cells.
20  optogenetics, whole-cell electrophysiology, molecular pharmacology and single cell RT-PCR in mice.
21                                          The molecular pharmacology and stoichiometry of this binding
22       Here, we have developed an integrative molecular pharmacology and structural biology approach i
23 coma research, including molecular genetics, molecular pharmacology, and the search for novel antigla
24                             In this issue of Molecular Pharmacology, Andreeva et al. (p.
25                             In this issue of Molecular Pharmacology, Bauer et al. (p.
26                 The studies in this issue of Molecular Pharmacology by Milojevic et al. merge these t
27                        This special issue of Molecular Pharmacology celebrates these 50 years of opio
28                             In this issue of Molecular Pharmacology, Dong et al. (p.
29                             In this issue of Molecular Pharmacology, Emanuel et al. report on a tyros
30 -atomic resolution and have great promise in molecular pharmacology, especially in the context of map
31 cular switches all contribute to the complex molecular pharmacology exhibited by mGlu receptor allost
32                             In this issue of Molecular Pharmacology, Groot-Kormelink et al. (page 559
33                             In this issue of Molecular Pharmacology, Hahn et al. (p.
34                  The substantial impact that Molecular Pharmacology has had on the field of pharmacol
35 effectors through heterotrimeric G-proteins, molecular pharmacology has probed the basic organization
36                                This issue of Molecular Pharmacology includes a study (p.
37                                This issue of Molecular Pharmacology is dedicated to Dr.
38                                 Although its molecular pharmacology is multifarious, efavirenz's prev
39                         A long-held tenet of molecular pharmacology is that canonical signal transduc
40                          One of the goals of molecular pharmacology is to understand the machinery th
41      In the study published in this issue of Molecular Pharmacology, Kohout et al. (p.
42                             In this issue of Molecular Pharmacology, Kundakovic et al. (p.
43             Two articles in recent issues of Molecular Pharmacology, Lane et al. and Galandrin and Bo
44     In an article presented in this issue of Molecular Pharmacology, Lim et al. (p.
45                      In the current issue of Molecular Pharmacology, Liu et al. (p.
46                             In this issue of Molecular Pharmacology, Luo et al. (p.
47                             In this issue of Molecular Pharmacology, Luo et al. present a study emplo
48                             In this issue of Molecular Pharmacology, Meyn et al. (p.
49 s has provided new insights into the complex molecular pharmacology of 17AAG and suggested new genes
50  that underscores the need to understand the molecular pharmacology of a compound's activity, includi
51 and adds significant new knowledge about the molecular pharmacology of a diverse range of clinically
52 t the first comprehensive examination of the molecular pharmacology of BK channels.
53 tool for unraveling the cellular biology and molecular pharmacology of both naturally occurring and s
54 ur understanding of anticancer drugs and the molecular pharmacology of cancer.
55 t al., 2019) provide unique snapshots of the molecular pharmacology of cannabinoids.
56     Our results improve understanding of the molecular pharmacology of CCR5 and help further elucidat
57 dition to providing useful insights into the molecular pharmacology of CYC202 in human cancer cells,
58                     We therefore studied the molecular pharmacology of CYC202 in human colon cancer c
59 re we describe the discovery, synthesis, and molecular pharmacology of delta-opioid receptor-selectiv
60  will highlight how our understanding of the molecular pharmacology of ER ligands has been utilized i
61 ng could provide valuable information on the molecular pharmacology of established and novel drugs.
62                 Further understanding of the molecular pharmacology of failing synapses in Alzheimer
63 tform (SyncroPatch 768PE) to investigate the molecular pharmacology of GS-967 and eleclazine on peak
64                          We investigated the molecular pharmacology of GS-967 and eleclazine on sodiu
65                                          The molecular pharmacology of inhalational anesthetics remai
66 ssing and strand transfer as well as for the molecular pharmacology of integrase inhibitors.
67                                 However, the molecular pharmacology of ligand binding to CXCR3 altern
68 ell cycle may also help us to understand the molecular pharmacology of microtubule-active drugs.
69 ur work provides important insights into the molecular pharmacology of NCC and a blueprint for develo
70 yrosine residues differentially affected the molecular pharmacology of orthosteric and allosteric lig
71                                 However, the molecular pharmacology of P2X receptors is poorly unders
72          The common and unique chemistry and molecular pharmacology of six FDA-approved siRNA therape
73 re useful pharmacological tools to probe the molecular pharmacology of the delta receptor and to expl
74  10 years, and consider our knowledge of the molecular pharmacology of the drug in the context of cli
75            Altogether, these data define the molecular pharmacology of the human P2X1 receptor laying
76 t the most extensive characterization of the molecular pharmacology of the most widely used CB2R liga
77 marizing the common and unique chemistry and molecular pharmacology of the six FDA-approved siRNA the
78              Further characterization of the molecular pharmacology of these and analogous compounds
79  PS-ASOs and research on all elements of the molecular pharmacology of these molecules.
80  information necessary for understanding the molecular pharmacology of these receptors.
81  information necessary for understanding the molecular pharmacology of this receptor, thus underlinin
82                             In this issue of Molecular Pharmacology, Oliveras-Reyes et al. (p.
83                     A study in this issue of Molecular Pharmacology on agonist-induced internalizatio
84                             In this issue of Molecular Pharmacology, Ou and Gean (p.
85    A remarkable new article in this issue of Molecular Pharmacology (p.
86 on in light of a new report in this issue of Molecular Pharmacology (p.
87        An article presented in this issue of Molecular Pharmacology (p.
88 the article by Zhang et al. in this issue of Molecular Pharmacology (p.
89                             In this issue of Molecular Pharmacology, Pannacione et al. provide eviden
90 ling the main characteristics of NQO2 from a molecular pharmacology perspective.
91 ses in the cell but remains a major focus of molecular pharmacology research.
92                      Herein, we describe the molecular pharmacology, safety, pharmacokinetics, and fu
93 d synthetic neuroactive steroid analogs with molecular pharmacology similar to allopregnanolone (SGE-
94                             In this issue of Molecular Pharmacology, Stirone et al. (p.
95                              Mutagenesis and molecular pharmacology studies revealed that TBPB activa
96 on two articles in the October 2015 issue of Molecular Pharmacology that investigate the role of mu-o
97                             In this issue of Molecular Pharmacology, the work by Culmsee et al. (p.
98 rmacology and Experimental Therapeutics, and Molecular Pharmacology These revisions relate to data an
99  true to the original goals for the journal, Molecular Pharmacology today remains an outstanding venu
100 s Perspective, former and current editors of Molecular Pharmacology, together with the guest editors
101                             In this issue of Molecular Pharmacology, Trankle et al. (p.
102                                A paradigm in molecular pharmacology was defined by design of rapid-ac
103   Collectively, the newly characterized FPR2 molecular pharmacology will facilitate the design of mor
104             Integration of the principles of molecular pharmacology with contemporary high-throughput
105 to hTA1 structure and function, contrast its molecular pharmacology with that of related receptors, a
106     In an article presented in this issue of Molecular Pharmacology, Yacoub et al. (p.
107                  An article in this issue of Molecular Pharmacology (Yost et al., p.
108                             In this issue of Molecular Pharmacology, Zaher et al. (p.
109                             In this issue of Molecular Pharmacology, Zhang et al. (p.

 
Page Top